S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal

Cytokinetics (CYTK) Stock Price, News & Analysis

$71.41
+0.26 (+0.37%)
(As of 03/27/2024 ET)
Today's Range
$69.88
$73.18
50-Day Range
$63.75
$84.80
52-Week Range
$25.98
$110.25
Volume
2.48 million shs
Average Volume
3.24 million shs
Market Capitalization
$7.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.00

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
7.8% Upside
$77.00 Price Target
Short Interest
Bearish
14.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.82mentions of Cytokinetics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$10.04 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.51) to ($3.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

325th out of 939 stocks

Pharmaceutical Preparations Industry

144th out of 436 stocks

CYTK stock logo

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

CYTK Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
CYTK Mar 2024 63.000 call
CYTK Mar 2024 69.000 put
CYTK Mar 2024 69.000 call
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
CYTK Mar 2024 62.000 call
CYTK Apr 2024 58.000 put
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
CYTK Aug 2024 30.000 put
CYTK Mar 2024 61.000 put
Q4 2023 CytomX Therapeutics Inc Earnings Call
CYTK Apr 2024 65.000 put
CYTK Apr 2024 110.000 call
CYTK Apr 2024 73.000 call
CYTK Apr 2024 72.000 put
CYTK Mar 2024 83.500 call
CYTK Mar 2024 72.000 put
CYTK Mar 2024 68.000 call
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTK
Employees
423
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$77.00
High Stock Price Target
$108.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+7.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-526,240,000.00
Net Margins
-6,988.63%
Pretax Margin
-6,988.63%

Debt

Sales & Book Value

Annual Sales
$7.53 million
Book Value
($3.94) per share

Miscellaneous

Free Float
99,091,000
Market Cap
$7.36 billion
Optionable
Optionable
Beta
0.69

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 60)
    CEO, President & Director
    Comp: $1.14M
  • Mr. Robert C. WongMr. Robert C. Wong (Age 56)
    VP & Chief Accounting Officer
    Comp: $463.75k
  • Dr. Fady Ibraham Malik FACC (Age 60)
    M.D., Ph.D., Executive Vice President of Research & Development
    Comp: $776.99k
  • Mr. Andrew M. Callos (Age 68)
    Executive VP & Chief Commercial Officer
    Comp: $745.4k
  • Dr. James A. Spudich Ph.D. (Age 82)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $21.94k
  • Mr. Jeff Lotz
    Vice President of Sales & Operations
  • Mr. Matt Yang
    Vice President of Corporate Finance and Financial Planning & Analysis
  • Mr. Steven M. Cook (Age 65)
    Senior Vice President of Supply Chain Operations & Technical Operations
  • Ms. Diane Weiser
    Senior Vice President of Corporate Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer

CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price target for 2024?

15 equities research analysts have issued 1 year target prices for Cytokinetics' shares. Their CYTK share price targets range from $42.00 to $108.00. On average, they expect the company's stock price to reach $77.00 in the next year. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2024?

Cytokinetics' stock was trading at $83.49 at the start of the year. Since then, CYTK shares have decreased by 14.5% and is now trading at $71.41.
View the best growth stocks for 2024 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to analysts' expectations of $7.62 million. The business's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period last year, the business earned ($1.45) EPS.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.24%), Vanguard Group Inc. (10.70%), Price T Rowe Associates Inc. MD (3.31%), RTW Investments LP (2.58%), Northern Trust Corp (1.08%) and First Turn Management LLC (0.82%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners